Repoxegen is developing a new, patented treatment for retinal- and neuro- degeneration. Our oral small molecule drug targets an enzyme that seems to be a central switch in shifting from chronic destructive inflammation to a restorative homeostasis which resolves inflammation. This target enzyme, a soluble epoxide hydrolase, is involved in fatty acid metabolism and is upstream of most inflammation signaling pathways. The therapeutic potential of this target is validated in models of retinal and neuro-degenerative disease, with multiple beneficial effects against markers of inflammation signaling pathways such as Il-6, p38 kinase, COX2, tau, and beta-amyloid that indicate a unique approach to MANY diseases of aging in an unexplored new drug platform. This approach allows us to address retinal and neuronal degenerative diseases that are poorly addressed with today’s available treatments and thus represent some of our aging society’s most significant unmet medical needs.